The plasminogen activators, streptokinase and urokinase, have a definite place in the management of acute major pulmonary embolism and extensive recent deep leg vein thrombosis. However, because the risk of bleeding is greater than with anticoagulant treatment, these drugs should be used only after careful consideration of the expected benefits and hazards to the individual patient. The value of plasminogen activators in other thromboembolic disorders and the usefulness of other fibrinolytic agents remain to be decided.
|Number of pages
|Published - 1976